Company · founded 2004

TheraSource (United States)

Manhasset, United States · therasourceinc.com

Manage this page

Citations, last 5 years: 31
Works, last 5 years: 4
h-index: 10
Scientists listed: 0
Grants since 2016: 16

Grants received

2022–2023 · research · R43

eCIRP-Neutralizing mAb for Acute Lung Injury in Sepsis

Max Brenner · TheraSource (United States) · funded by National Institutes of Health

$129.8k

2022–2023 · research · R43

eCIRP-Neutralizing mAb for Acute Lung Injury in Sepsis

Max Brenner · TheraSource (United States) · funded by National Institutes of Health

$259.5k

2019–2021 · research · R43

A New Therapy for Acute Kidney Injury

Max Brenner · TheraSource (United States) · funded by National Institutes of Health

$160.5kAcute Kidney Injury Research

2019–2021 · research · R43

A New Therapy for Acute Kidney Injury

Max Brenner · TheraSource (United States) · funded by National Institutes of Health

$139.5kAcute Kidney Injury Research

2017–2019 · research · R41

Preclinical Development of a Novel Small Molecule Drug for Sepsis

Max Brenner · TheraSource (United States) · funded by National Institutes of Health

$111.2k

2017–2018 · research · R41

Preclinical Development of a Novel Small Molecule Drug for Sepsis

Max Brenner · TheraSource (United States) · funded by National Institutes of Health

$222.2k

2016–2018 · research · R43

A Novel Recombinant Protein as an Effective Therapy for Acute Kidney Injury

Weng-Lang Yang · TheraSource (United States) · funded by National Institutes of Health

$222.5kPhagocytosis and Immune Regulation

2016–2018 · research · R43

rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock

Weng-Lang Yang · TheraSource (United States) · funded by National Institutes of Health

$112.5kTrauma, Hemostasis, Coagulopathy, Resuscitation

2016–2022 · research · R44

rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock

Max Brenner · TheraSource (United States) · funded by National Institutes of Health

$505.6kTrauma, Hemostasis, Coagulopathy, Resuscitation

2016–2017 · research · R43

rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock

Weng-Lang Yang · TheraSource (United States) · funded by National Institutes of Health

$225kTrauma, Hemostasis, Coagulopathy, Resuscitation

2016–2023 · research · R44

rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock

Max Brenner · TheraSource (United States) · funded by National Institutes of Health

$986.4kTrauma, Hemostasis, Coagulopathy, Resuscitation

2016–2018 · research · R43

A Novel Recombinant Protein as an Effective Therapy for Acute Kidney Injury

Weng-Lang Yang · TheraSource (United States) · funded by National Institutes of Health

$112.8kPhagocytosis and Immune Regulation

2016–2022 · research · R44

rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock

Max Brenner · TheraSource (United States) · funded by National Institutes of Health

$505.6kTrauma, Hemostasis, Coagulopathy, Resuscitation

2014–2024 · research · R44

A Novel Recombinant Protein for Mitigating Acute Radiation Injury

Wayne Chaung · TheraSource (United States) · funded by National Institutes of Health

$974.4kEffects of Radiation Exposure

2014–2023 · research · R44

A Novel Recombinant Protein for Mitigating Acute Radiation Injury

Wayne Chaung · TheraSource (United States) · funded by National Institutes of Health

$974.4kEffects of Radiation Exposure

2014–2023 · research · R44

A Novel Recombinant Protein for Mitigating Acute Radiation Injury

Wayne Chaung · TheraSource (United States) · funded by National Institutes of Health

$974.4kEffects of Radiation Exposure